Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical Cancer Research

• Publication date

  2004-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-04-0220PMID 15328174
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer

  2004cited by this paper
• Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer

  2004cited by this paper
• Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

  2004cited by this paper
• KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations.

  2004cited by this paper
• Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival

  2004cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Breast cancer classification and prognosis based on gene expression profiles from a population-based study

  2003influential reference
• Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept

  2003cited by this paper
• Cytogenetic Alterations and Cytokeratin Expression Patterns in Breast Cancer: Integrating a New Model of Breast Differentiation into Cytogenetic Pathways of Breast Carcinogenesis

  2002cited by this paper
• HER-Targeted Tyrosine-Kinase Inhibitors

  2002cited by this paper
• Molecular portraits and the family tree of cancer

  2002cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes.

  2002cited by this paper
• Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays.

  2002cited by this paper
• The Stanford Microarray Database

  2001cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Tissue microarrays for gene amplification surveys in many different tumor types.

  1999cited by this paper
• Tissue microarrays for high-throughput molecular profiling of tumor specimens

  1998cited by this paper
• Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas

  1998cited by this paper
• Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.

  1997cited by this paper
• An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin

  1992cited by this paper
• Basal cell-specific and hyperproliferation-related keratins in human breast cancer.

  1991cited by this paper
• Neoadjuvant (preoperative) chemotherapy for breast cancer

  1985cited by this paper
• A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship

  1970cited by this paper
• Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome

  year unknowncited by this paper
• Copyright © American Society for Investigative Pathology Tissue Microarray Validation of Epidermal Growth Factor Receptor and SALL2 in Synovial Sarcoma with Comparison to Tumors of Similar Histology

  year unknowncited by this paper

• Treatment of ER-positive breast cancer with FDA-approved aromatase inhibitors.

  2026cites this paper
• Assessment of SOX2 performance as a marker for circulating cancer stem-like cells (CCSCs) identification in advanced breast cancer patients using CytoTrack system

  2025cites this paper
• Adenoid cystic carcinoma of the breast with aggressive behavior: A case report and review of the literature

  2025cites this paper
• PAM50 Intrinsic Subtypes and Immunity Status in Prognosis of Triple-Negative Breast Cancer: A Retrospective Cohort Study

  2025cites this paper
• Microstructural diffusion MRI for differentiation of breast tumors and prediction of prognostic factors in breast cancer

  2025cites this paper
• Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action

  2025cites this paper
• The Cytochrome CYP4 in Breast and Other Cancers

  2025cites this paper
• Ketone body, as an emerging modulator of metabolic reprogramming and epigenetics in breast cancer

  2025cites this paper
• Role of PARP Inhibitors: A New Hope for Breast Cancer Therapy

  2025influential citation
• Adenoid cystic carcinoma of the breast, from diagnosis to management: a case report

  2025cites this paper
• Pharmacological CLK inhibition disrupts SR protein function and RNA splicing blocking cell growth and migration in TNBC

  2025cites this paper
• B cells enhance IL-1 beta driven invasiveness in triple negative breast cancer

  2025cites this paper
• Receptor Tyrosine Kinase Profiling Identifies Chronic Constitutive Floodgate Oxidative Signaling in Glutathione-Independent Human Mammary Luminal Progenitor Cells

  2025cites this paper
• Synergic anti-tumor effects of photodynamic therapy and resveratrol on triple-negative breast cancer cells

  2025cites this paper
• Exploration of Traditional Chinese Medicine Comprehensive Treatment of Triple Negative Breast Cancer Based on Molecular Pathological Mechanism

  2025cites this paper
• Female breast cancer classification using immunohistochemistry biomarkers staining in Botswana

  2025cites this paper
• FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

  2025cites this paper
• Breast Cancer Heterogeneity in Latin America: A Scoping Review of Clinical‐Pathological Characteristics, Molecular Subtypes, and Survival

  2025cites this paper
• Chemosensitization and Molecular Docking Assessment of Dio-NPs on Resistant Breast Cancer Cells to Tamoxifen

  2025cites this paper
• Extracellular Vesicles Derived from Breast Cancer Cells: Emerging Biomarkers of Tumor Progression and Metastasis

  2025cites this paper
• c-Myc knockdown restores tamoxifen sensitivity in triple-negative breast cancer by reactivating the expression of ERα: the central role of miR-152 and miR-148a.

  2025cites this paper
• The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype

  2025cites this paper
• The utility of immunohistochemistry-based biomarkers in predicting the pathological complete response in early-stage triple-negative breast cancer.

  2025cites this paper
• BKS-112, a Selective Histone Deacetylase 6 Inhibitor, Suppresses Triple-Negative Breast Cancer Cells via AKT/mTOR Pathway

  2025cites this paper
• Molecular subtyping and target identification in triple negative breast cancer through immunohistochemistry biomarkers

  2025cites this paper
• Clinical Significance of Fragile X Syndrome 2 (FXR2) in Breast Cancer

  2025cites this paper
• The role of CXC chemokines and receptors in breast cancer

  2025cites this paper
• ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling

  2025cites this paper
• Epidemiological Profile of Breast Cancer Phenotypes in Rural Southern West Bengal, India

  2025cites this paper
• Multi-gene expression assays in breast cancer: a literature review

  2025cites this paper
• Ferroptosis-related differential gene expression and immune correlates in luminal a subtype breast cancer: a prognostic model approach

  2025cites this paper
• The BMP4-BMPR1A axis represses BRCA1 in mammary stem cells and contributes to tumor initiation

  2025cites this paper
• Beta-cyclodextrin formulation of a disulfide-bond disrupting agent for improved systemic exposure

  2025cites this paper
• Anti-cancer drug sensitivity testing and preclinical evaluation of the anti-cancer potential of WEE1 inhibitor in triple-negative breast cancer patient-derived organoids and xenograft models

  2025cites this paper
• Basal-like subtype of esophageal adenocarcinoma and it’s morphological, molecular and clinical characteristics

  2025cites this paper
• Reactivation of Multipotency in the Mammary Gland – a Ripple in the Pond and a Turn of the Tide

  2025cites this paper
• Immunohistochemical Breast Cancer Profiling Among Iraqi Women: Molecular Subtype Classification, Clinicopathology Associations, and Treatment‐Decision Making Tools: A Cross‐Sectional Study

  2025cites this paper
• Natural Products Targeting the EGFR/HER2 Axis in Tumorigenesis: Interpretation of Molecular Mechanisms and Recent Insights Into Synergistic Strategies for Cancer Therapy

  2025cites this paper
• Localized Hydrogel-Mediated Docetaxel-Carboplatin Combination Chemotherapy Targets Ganglioside Metabolism to Mitigate Tumor Progression.

  2025cites this paper
• Establishment and Partial Characterization of Canine Mammary Tumor Cell Lines

  2025cites this paper
• Discovery and structural-activity relationship of N-benzyl-2-fluorobenzamides as EGFR/HDAC3 dual-target inhibitors for the treatment of trithe ple-negative breast cancer.

  2025cites this paper
• Intermediate Filaments in Breast Cancer Progression, and Potential Biomarker for Cancer Therapy: A Narrative Review

  2024cites this paper
• Spectrum of Ductal Carcinoma In Situ (DCIS) Lesions of the Breast: From Morphology to Molecular Characteristics

  2024cites this paper
• Prognostic Significance of Combining Cytokeratin-19, E-Cadherin and Ki-67 Analysis in Triple-Negative Breast Cancer with Basal-Like and Non-Basal-Like Phenotype

  2024cites this paper
• Breast cancer stem cells origins and the memory stem cells: clinical significance of biomarkers and the active therapeutic approaches

  2024cites this paper
• B cells enhance IL-1 beta driven invasiveness in triple-negative breast cancer

  2024cites this paper
• CK5/6 Expression in Molecular Subtypes of Invasive Ductal Carcinoma

  2024cites this paper
• Comparison among Various Prognostic Pathologic Markers Revealed Significantly Poorer Prognosis in Non-basal-like than in Basal-like Triple Negative Breast Cancer

  2024influential citation
• ALDH1 subtype-specific inhibitor targets key cancerous epithelial cell populations in aggressive subtypes of breast cancer

  2024cites this paper
• The Value of Whole-Volume Radiomics Machine Learning Model Based on Multiparametric MRI in Predicting Triple-Negative Breast Cancer

  2024cites this paper
• Age- and ethnic-driven molecular and clinical disparity of East Asian breast cancers

  2024cites this paper
• Smart Accumulating Dual-Targeting Lipid Envelopes Equipping Oncolytic Adenovirus for Enhancing Cancer Gene Therapeutic Efficacy.

  2024cites this paper
• Advanced Insights into Competitive Endogenous RNAs (ceRNAs) Regulated Pathogenic Mechanisms in Metastatic Triple-Negative Breast Cancer (mTNBC)

  2024cites this paper
• Investigating the clinical significance of OAS family genes in breast cancer: an in vitro and in silico study

  2024cites this paper
• Promoting effect of Sunset Yellow on N-methyl N-nitrosourea-induced rat mammary carcinogenesis: Implications of molecular mechanisms.

  2024cites this paper
• Adenoid Cystic Carcinoma of the breast——a case report and review of the literature

  2024cites this paper
• Prevalence of basal-like phenotype in triple-negative invasive breast carcinomas and a review of the literature

  2024cites this paper
• Recent Studies on Aromatase and EGFR Involved in Breast Cancer and their Inhibitors

  2024cites this paper
• Anti-EGFR Antibody–Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth

  2024cites this paper
• EGFR and Hippo signaling pathways are involved in organophosphate esters–induced proliferation and migration of triple-negative breast cancer cells

  2024cites this paper
• Marine-derived EGFR inhibitors: novel compounds targeting breast cancer growth and drug resistance

  2024cites this paper
• Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer

  2024cites this paper
• Clinical, Histopathological, and Immunohistochemical Characteristics of Predictive Biomarkers of Breast Cancer: A Retrospective Study.

  2024cites this paper
• Targeted polymer lipid hybrid nanoparticles for in-vitro siRNA therapy in triple-negative breast cancer

  2024cites this paper
• Insights into the Emerging Therapeutic Targets of Triple-negative Breast Cancer.

  2024cites this paper
• Upregulation of the histone γ-H2AX correlates with worse patient survival and basal-like subtype in pancreatic ductal adenocarcinoma

  2024cites this paper
• Clinical Profile of Triple-Negative Breast Cancer: A Hospital-Based Study

  2024cites this paper
• Osteopontin in cancer.

  2024cites this paper
• Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes

  2024cites this paper
• VGLL1 stabilization of cytoplasmic TAZ promotes EGFR expression and maintains tumor initiating cells in breast cancer independent of TEAD.

  2024cites this paper
• Detection of KRAS Mutations in Triple-negative Breast Cancers by Polymerase Chain Reaction

  2024cites this paper
• The value of oestrogen receptor, progesterone receptor and keratins 5 and 14 immunohistochemistry in the evaluation of epithelial proliferations at cauterised margins in breast-conserving surgery specimens.

  2024cites this paper
• Prognostic Value of “Basal-like” Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative Breast Cancer

  2024influential citation
• Exploring the contrasts: in-depth analysis of human and canine mammary tumors - discoveries at the frontier

  2024cites this paper
• Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers

  2024cites this paper
• Cellular Responses Induced by NCT-503 Treatment on Triple-Negative Breast Cancer Cell Lines: A Proteomics Approach

  2024cites this paper
• Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy

  2024cites this paper
• Donkey milk inhibits tumor growth by inducing apoptosis, pyroptosis and modulation of Th1/Th2 responses in a 4T1 murine breast cancer model

  2024cites this paper
• The role of IMP3 immunohistochemistry expression in triple-negative breast cancer as a prognostic factor

  2024cites this paper
• Immunohistochemical Observation and Correlation of Epidermal Growth Factor Receptor Downstream Signaling Proteins with Plasma Medium-Chain Fatty Acids Levels in Breast Cancer

  2024cites this paper
• Endosomal protein expression of γ1-adaptin is associated with tumor growth activity and relapse-free survival in breast cancer

  2024cites this paper
• Glucocorticoid Receptors Orchestrate a Convergence of Host and Cellular Stress Signals in Triple Negative Breast Cancer.

  2024cites this paper
• Survival Analysis in Metastasis Breast Cancer with HER-2 Type That Received Vinorelbine And Capecitabine Chemotherapy at Prof. Dr.I.G.N.G. Ngoerah Central General Hospital

  2024cites this paper
• Immuno-Modulatory Effects of Korean Mistletoe in MDA-MB-231 Breast Cancer Cells and THP-1 Macrophages

  2023cites this paper
• Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer

  2023cites this paper
• Target-Oriented Classification of Triple-negative Breast Cancer

  2023cites this paper
• Analysis of clinicopathological characteristics and prognostic factors of early‐stage human epidermal growth factor receptor 2 (HER2)‐low breast cancer: Compared with HER2‐0 breast cancer

  2023cites this paper
• Extracellular Vesicles in Triple–Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential

  2023cites this paper
• Breast Carcinoma With Tubulopapillary Features Has a Distinct Immunophenotypic and Molecular Signature: A Report of Two Tumors and Literature Review

  2023cites this paper
• MicroRNAs as Molecular Biomarkers for the Characterization of Basal-like Breast Tumor Subtype

  2023cites this paper
• Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13

  2023cites this paper
• In silico investigation of a novel anti-EGFR scFv-IL-24 fusion protein induces apoptosis in malignant cells

  2023cites this paper
• Clinicopathologic study of triple-negative breast cancer with special reference to basal-like breast cancer phenotype in a tertiary care hospital of Eastern India

  2023cites this paper
• Recent progress in Cetuximab-based treatment for Triple-NegativeBreast Cancer

  2023cites this paper
• FMRP expression in primary breast tumor cells correlates with recurrence and specific site of metastasis

  2023cites this paper
• Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook

  2023cites this paper
• Correlation of PKM2 Expression With HER2/neu and Additional Breast Cancer Biomarkers and its Prognostic Significance

  2023cites this paper
• Breast Cancer Prognostic Hub Genes Identified by Integrated Transcriptomic and Weighted Network Analysis: A Road Toward Personalized Medicine

  2023cites this paper
• Epidermal growth factor potentiates EGFR(Y992/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium

  2023cites this paper
• Breast cancer in young Indian women: factors, challenges in screening, and upcoming diagnostics

  2023cites this paper